Loading clinical trials...

ALSENLITE: Senolytics for Alzheimer's Disease | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

ALSENLITE: Senolytics for Alzheimer's Disease

ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease

NCT04785300•Mayo Clinic

Summary

This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

Detailed Description

The underlying processes driving chronic neurodegeneration in Alzheimer's disease (AD) and related neurodegenerative disorders are largely unknown. Aging is the major risk factor for AD. Moreover, individuals with AD suffer from significantly more co-morbid conditions than demographically matched older adults. This study is an open-label pilot study of intermittent administration of the senolytic drug regimen Dasatinib (D) + Quercetin (Q) in symptomatic adults over 55 with clinical diagnosis of probable Alzheimer's Disease and Alzheimer's biomarker positivity by tau-PET.

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Men and women of age 55 years and older at the time of enrollment
•2. Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)
•3. Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months
•4. Body Mass Index (BMI) within range of 19 - 50 kg/ m2
•5. Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
•6. Participants must have no plans to travel over the \~3 months between Visits 3 and 14 that interfere with study visits
•7. Tau positivity by brain PET imaging
•8. Adequate blood counts i.e. platelets \> 50,000 per microliter; HB \> 9/dL, and ANC \> 1000 per microliter
•9. Availability and consent from a LAR.

Exclusion Criteria

•1. Unwilling or unable to give informed consent
•2. Pregnancy
•3. QTc \> 450 msec on baseline ECG
•4. MRI contraindications
•5. Presence of uncontrolled psychiatric disorder (as per clinical judgment)
•6. Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
•7. Substance or alcohol abuse (current alcohol use \> 3 alcoholic beverage/day or \> 21 per week and as per clinical judgment)
•8. Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)
•9. Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months
•10. Chronic heart failure (as per clinical judgment)
+25 more criteria

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

July 6, 2022

Primary Completion Date

June 1, 2026

Completion Date

June 1, 2026

Last Updated

January 22, 2026

Enrollment

ESTIMATED participants

Conditions

Mild Cognitive ImpairmentAlzheimer Disease

Interventions

Dasatinib

DRUG

Quercetin

DRUG

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 22, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ALSENLITE: Senolytics for Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases